At Botanix, our mission is to address the growing demand for innovative solutions for common, yet overlooked, skin diseases and infections. As a lean multi-disciplinary team of global leaders in dermatology, clinical research and commercialisation, we harness our expertise to deliver first-in-class treatments at the highest industry standards.
Executive Chairman
Vince Ippolito is the Executive Chairman of Botanix Pharmaceuticals and responsible for the company’s commercial operations worldwide. Mr Ippolito is based in Phoenix USA, where Botanix is building its commercial operations functions. Mr Ippolito is a leading pharmaceutical expert who has over 30 years of experience in the industry, including more than 20 years in dermatology. Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine and played a leading role in two of the largest dermatology acquisitions completed in the past decade, with combined valuations of $7.8 billion. He served as the Chief Commercial Officer Executive Vice President of Anacor Pharmaceuticals, a dermatology based biopharmaceutical company, until September 2017, where he was responsible for developing marketing and sales functions, as well as strategising the company’s product portfolio. Previously, Mr Ippolito was Executive Vice President and Chief Commercial Officer at Medicis, an industry leading dermatology and aesthetic company.
Non-Executive Director
Dr Bill Bosch is an accomplished pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix™ drug delivery technology, used in four FDA-approved prescription drug products. Earlier in his career Dr. Bosch was a pioneer in the application of nanotechnology to pharmaceutical product development. He served as a co-founder of NanoSystems LLC in 1995 and was co-inventor of NanoCrystal® Technology, leading to the successful development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
Non-Executive Director
Patricia Walker, MD, PhD, is a practising dermatologist specialising in medical and aesthetic dermatology. She has served in key leadership roles, including President and head of R&D for Brickell Biotech; Chief Medical Officer for Kythera Biopharmaceuticals, Inc.; Executive Vice President and Chief Scientific Officer for Allergan Medical Aesthetics; and Vice President and Dermatology Therapeutic Area Head at Allergan. She was Chief Medical Advisor for Botanix and is a consultant for prominent dermatology pharmaceutical companies.companies.
Dr Walker received her medical degree and served her dermatology residency at the University of Iowa College of Medicine. She then completed a research fellowship at the National Institute of Health’s Dermatology Branch. Dr Walker has over 60 publications in medical and scientific journals and has earned more than two dozen academic and professional honours.
Executive Director
Mr Morissey joined Botanix in March 2024. Mr Morissey is a Chartered Accountant with extensive experience across the resources sector, including serving as Chief Financial Officer of a number of ASX-listed mining and mineral exploration companies. His experience spans equity and debt capital markets, mergers and acquisitions, corporate governance and the financial management of mining and exploration activities across multiple jurisdictions. Mr Morissey began his career in public practice and spent 15 years with EY, KPMG and Grant Thornton, including as a Director. He is currently a director of Heavy Rare Earths Limited (ASX: HRE) and Jacaranda Resources Limited, which is undertaking an initial public offering ahead of a proposed ASX listing.
Non-Executive Director
Mr Bickley joined Botanix in October 2025. He has more than 15 years’ experience in corporate governance, legal and advisory roles across Australian and international organisations, including listed companies, professional services firms and statutory agencies. Mr Bickley has extensive experience advising boards and senior executives on corporate governance and listed company matters. Mr Bickley holds a Bachelor of Laws from the University of Essex and is a Fellow of both the Governance Institute of Australia and the Chartered Governance Institute.
Chief Executive Officer
Dr McKibbon has more than 20 years of leadership experience in the pharmaceutical industry, including working as Senior Vice President, Sales and Marketing at Anacor Pharmaceuticals; Senior Vice President, Worldwide Commercial Operations at Dermavant Science; and Vice President, Dermatology and Immunology at Medicis Pharmaceuticals. Dr McKibbon has launched 15 products, including 11 in dermatology, and managed over 30 dermatology products. He also played a significant role in two of the world’s largest dermatology acquisitions with combined valuations of $7.8 billion. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University’s Stetson School of Business and Economics and a Doctor of Pharmacy from Mercer University’s Southern School of Pharmacy.
Chief Financial Officer
Chris Lesovitz is a financial executive with over 20 years of experience. As Chief Financial Officer, he oversees all aspects of the company’s financial operations, including accounting, financial planning and analysis, treasury, capital markets, and investor relations. He brings extensive expertise in financial leadership during growth and transformation phases, with a proven record in supporting commercial execution, managing liquidity, and partnering with senior leadership to create value. In close collaboration with the executive team, he strives to align financial strategy with operational priorities, strengthen financial discipline, and support the company’s long-term growth objectives. Mr Lesovitz holds a Bachelor of Science in Accounting from Villanova University and is a Certified Public Accountant.
Chief Legal and Compliance Officer
Carey Herbert has over 25 years of experience in corporate securities law and is the Chief Legal and Compliance Officer at Botanix Pharmaceuticals, handling governance, compliance, intellectual property and strategic transactions, such as capital raises and asset acquisitions. Previously, she was Vice President, Legal at Dermavant Sciences, guiding licensing, financings, SEC reporting, and legal oversight of contracting, compliance and corporate transactions. From 2008–2016, Carey was President and Assistant General Counsel for a real estate investment sponsor, managing legal, compliance and securities broker-dealer matters. She also worked for eight years in the corporate securities practice at an international law firm, specialising in securities offerings, IPOs, and M&A, and gained experience at the SEC's Enforcement Division in New York City. Before law, she taught business law and ethics at the University of Arizona. She holds degrees from the University of Alberta and Arizona, including a PhD and JD.
Chief Operating Officer
Paul Seaback is an accomplished biopharmaceutical executive with over three decades of industry experience, including senior leadership roles at leading pharmaceutical organisations and companies scaling for growth. Mr Seaback’s career extends from drug substance and drug product site leadership roles to corporate-level oversight of end-to-end supply functions and business operations, consistently driving growth. Most recently, Mr Seaback was Chief Technical Officer at Dermavant Sciences (a Roivant company) until its acquisition by Organon, where he developed the global CMC and technical organisation from a clinical stage into a commercial entity. Prior to Dermavant, Mr Seaback was the VP of Operations & Supply until its acquisition by Roche. He has also held global leadership roles at Gilead, Medicis, Hospira, Mayne and Novartis, supporting the commercialisation of products including Sovaldi/Harvoni, Vtama, Solodyn, Truvada and Vemlidy.
Senior Vice President Sales and Marketing
Dan Listemann is Senior Vice President, Sales and Marketing at Botanix Pharmaceuticals, where he leads commercial activities for Sofdra®, including its sales execution, patient access pull-through, marketing, marketing operations and market development initiatives. Mr Listemann brings 19 years of pharmaceutical and dermatology commercialisation experience, having held senior roles in sales, sales training, and professional relations at Dermavant Sciences, Incyte, Pfizer, Anacor Pharmaceuticals, Valeant Pharmaceuticals, and GlaxoSmithKline. He supported the launch of seven successful dermatology products before joining Botanix.
This blend of deep dermatology expertise and commercial execution supports Botanix Pharmaceuticals’ efforts to expand patient access and drive long-term growth.
Head of Corporate Communications
David Morgan was an advertising agency principal for more than 30 years. His diverse client roster included Intel, Citibank, and Qwest (CenturyLink), among others. He has extensive experience in direct response advertising.
He founded and managed the in-house advertising agency at Medicis Pharmaceuticals for13 years. Mr Morgan and his team launched a dozen products and line extensions, including Solodyn, which was the best-selling dermatology product in the United States at one time.
An award-winning creative director, writer, and designer, Mr Morgan’s clarity of vision leads him to discover the insights that reside at the heart of successful advertising campaigns.